Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 10, 2004 Alyce Lomax	Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.
The Motley Fool March 22, 2004 Alyce Lomax	Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.
The Motley Fool May 5, 2004 Mike Cianciolo	CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways.
The Motley Fool August 3, 2004 Rich Duprey	Penney Kicks Drugstore Habit The retailer has completed its sale of Eckerd Drugs to focus on selling clothes. While investors can and should enjoy Penney's current clear-eyed plans, they ought to keep a watchful eye out for any relapse.
The Motley Fool June 2, 2004 Alyce Lomax	Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?
The Motley Fool July 6, 2004 Alyce Lomax	Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.
The Motley Fool May 9, 2005 Timothy M. Otte	Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note.
The Motley Fool December 23, 2003 Dave Marino-Nachison	Duane Reade's NY Story The well-known New York drugstore chain is going private after just under six years.
The Motley Fool April 5, 2004 Dave Marino-Nachison	Finally, Eckerd Sells J.C. Penney's drugstore operation will be split between CVS and Jean Coutu.
The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool January 5, 2004 Jeff Hwang	Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.
The Motley Fool March 24, 2004 Dave Marino-Nachison	Eking Out an Eckerd Deal Investors are still waiting for a new leader to be crowned in the U.S. drugstore business.
The Motley Fool July 6, 2004 Steven Mallas	Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%.
The Motley Fool February 2, 2005 Alyce Lomax	CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.
The Motley Fool October 5, 2007 Timothy M. Otte	CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition.
The Motley Fool January 4, 2008 Timothy M. Otte	Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.
The Motley Fool July 7, 2004 Steven Mallas	CVS's Bright Picture Send CVS your digital photos over the Net, pick them up the next day. While competitors are sure to follow suit, this still shows how intellegent and creative this drugstore blue chip can be.
The Motley Fool February 12, 2004 Dave Marino-Nachison	CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January.
The Motley Fool June 21, 2004 Seth Jayson	Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.
The Motley Fool January 13, 2004 Alyce Lomax	CVS Fever Drug stores benefit from the flu bug, but for how much longer?
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.
The Motley Fool June 25, 2004 Steven Mallas	Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio?
The Motley Fool March 5, 2004 Dave Marino-Nachison	Longs Coming Up Short Investors who bid on a Longs buyout haven't been rewarded in recent months.
The Motley Fool August 15, 2005 Bobby Shethia	Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.
The Motley Fool September 7, 2004 Seth Jayson	Rejecting Rite Aid Shares of the drugstore chain droped 13%, and may prove to be a bargain if this is indeed a temporary slowdown and management can deliver more robust growth.
The Motley Fool September 27, 2007 Ryan Fuhrmann	Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired.
The Motley Fool September 27, 2004 Phil Wohl	Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27.
The Motley Fool June 11, 2007 Mike Cianciolo	Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.
The Motley Fool March 9, 2004 Alyce Lomax	February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers.
National Real Estate Investor February 1, 2006 Christine Perez	Drugstore Addiction Drugstores are offering a healthy alternative for buyers of commercial real estate. Even as chains add new locations at a record pace, they're quietly overtaking grocery-anchored centers as a preferred product type among retail investors.
The Motley Fool April 8, 2004 Seth Jayson	Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line.
The Motley Fool November 10, 2004 Dave Marino-Nachison	Investors Adjusting to Larger CVS The drugstore company's chains have done nothing but rise since the Eckerd buy. Investors have pulled the company's shares steadily upward since the merger closed.
The Motley Fool February 26, 2004 Alyce Lomax	Pinching J.C. Penney Eckerd is still a pain, but will Penney fly when it's on its own? Penney's reported a net loss of $1.07 billion, or $3.42 per share, as compared to earnings of $202 million, or $0.68 per share, in the same quarter last year.
The Motley Fool January 8, 2007 Matthew Crews	CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note.
The Motley Fool November 9, 2005 Steven Mallas	CVS Needs Rx for Cash The drugstore chain has the prescription for earnings growth, but investors need to keep an eye on free cash flow.
The Motley Fool July 6, 2007 Timothy M. Otte	Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...
The Motley Fool February 3, 2006 Nathan Parmelee	CVS Looks Healthy The drugstore chain handles acquisitions without faltering -- this stock may be worth considering.
The Motley Fool September 14, 2006 Ryan Fuhrmann	Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.
The Motley Fool March 26, 2007 Ryan Fuhrmann	Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note.
The Motley Fool June 26, 2007 Ryan Fuhrmann	Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down.
The Motley Fool March 23, 2011 Andrew Bond	What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount.
The Motley Fool August 1, 2007 Ryan Fuhrmann	Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one.
The Motley Fool September 24, 2004 Seth Jayson	Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards.
The Motley Fool April 13, 2007 Ryan Fuhrmann	Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial.
The Motley Fool June 29, 2007 Ryan Fuhrmann	Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note.
The Motley Fool March 9, 2005 Steven Mallas	CVS Comps Feast on Flu CVS enjoys a nice jump in same-store sales for the month of February -- thanks, in part, to colds and the flu.
The Motley Fool August 8, 2005 Mike Cianciolo	A Cautiously Optimistic CVS The retail pharmacy nudges guidance up after an impressive quarter. All things considered, the outlook seems bright for investors in this company.
BusinessWeek September 19, 2005 Gene G. Marcial	CVS' Ever-Expanding Aisles According to analysts, the aging population and improving pipeline of new drugs will help the retail pharmacy achieve its goal of 15% overall long-term earnings growth. Investors, take note.
The Motley Fool July 5, 2005 Alyce Lomax	Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.
The Motley Fool September 26, 2007 Ryan Fuhrmann	Foolish Forecast: Does Rite Aid Have the Right Rx? The retail pharmacy is set to release it second-quarter financial results. Investors, here is what you can expect to see.